Immuneering Corp 8-K

What Happened
Immuneering Corporation (IMRX) filed a Form 8‑K on June 15, 2026 announcing that the Board appointed Andrew Gengos as Chief Financial Officer and Treasurer, effective upon commencement of his employment expected on or before July 16, 2026. The Board designated Mr. Gengos as the company’s principal financial officer; Mallory Morales will remain Senior Vice President Finance and Chief Accounting Officer and continue as principal accounting officer.

Key Details

• Appointment filed via 8‑K on June 15, 2026; expected employment start on or before July 16, 2026.
• Compensation: $530,000 annual base salary and target discretionary annual bonus of 40% of base salary.
• Equity inducement: option to purchase 650,000 shares under the 2025 Employment Inducement Award Plan, contingent on his start date.
• Severance: if terminated without cause or resigns for good reason, eligible for 12 months’ base salary, unpaid prior-year bonus, and COBRA premium coverage up to 12 months; enhanced change‑in‑control package adds a payment equal to 1.0x target bonus and accelerated vesting of certain equity awards.
• Background: Mr. Gengos, age 61, most recently CFO at Terns Pharmaceuticals (Feb 2025–May 2026) and previously held senior finance and executive roles at LeonaBio, Cyteir, Amgen and others. No family ties or related‑party transactions disclosed.

Why It Matters
A new CFO is a material executive change that can affect financial strategy, reporting and investor communications. The appointment brings experienced biopharma financial leadership and provides continuity on accounting (Ms. Morales remains principal accounting officer). Investors should note the potential dilution from a 650,000‑share option grant and the company’s potential severance obligations (12 months’ pay plus change‑in‑control protections) disclosed in the filing.